Annual EBITDA:
$589.48M+$97.04M(+19.71%)Summary
- As of today, AMRX annual EBITDA is $589.48 million, with the most recent change of +$97.04 million (+19.71%) on December 31, 2024.
- During the last 3 years, AMRX annual EBITDA has risen by +$131.76 million (+28.79%).
- AMRX annual EBITDA is now at all-time high.
Performance
AMRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
$174.14M+$16.41M(+10.41%)Summary
- As of today, AMRX quarterly EBITDA is $174.14 million, with the most recent change of +$16.41 million (+10.41%) on June 30, 2025.
- Over the past year, AMRX quarterly EBITDA has increased by +$21.13 million (+13.81%).
- AMRX quarterly EBITDA is now -19.35% below its all-time high of $215.91 million, reached on March 1, 2010.
Performance
AMRX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$626.64M+$21.13M(+3.49%)Summary
- As of today, AMRX TTM EBITDA is $626.64 million, with the most recent change of +$21.13 million (+3.49%) on June 30, 2025.
- Over the past year, AMRX TTM EBITDA has increased by +$68.81 million (+12.34%).
- AMRX TTM EBITDA is now at all-time high.
Performance
AMRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
AMRX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +19.7% | +13.8% | +12.3% |
| 3Y3 Years | +28.8% | +50.4% | +50.5% |
| 5Y5 Years | +182.4% | +127.5% | +74.5% |
AMRX EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +33.8% | at high | +82.3% | at high | +55.3% |
| 5Y | 5-Year | at high | +182.4% | at high | +115.2% | at high | +74.5% |
| All-Time | All-Time | at high | +3097.4% | -19.4% | +1357.3% | at high | +3110.5% |
AMRX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $174.14M(+10.4%) | $626.64M(+3.5%) |
| Mar 2025 | - | $157.72M(+8.0%) | $605.51M(+2.7%) |
| Dec 2024 | $589.48M(+19.7%) | $146.05M(-1.8%) | $589.48M(+3.2%) |
| Sep 2024 | - | $148.73M(-2.8%) | $571.20M(+2.4%) |
| Jun 2024 | - | $153.00M(+8.0%) | $557.83M(+3.6%) |
| Mar 2024 | - | $141.69M(+10.9%) | $538.59M(+9.4%) |
| Dec 2023 | $492.44M(+11.8%) | $127.77M(-5.6%) | $492.44M(-2.3%) |
| Sep 2023 | - | $135.36M(+1.2%) | $503.84M(+6.1%) |
| Jun 2023 | - | $133.76M(+40.0%) | $474.69M(+3.9%) |
| Mar 2023 | - | $95.55M(-31.3%) | $456.70M(+3.3%) |
| Dec 2022 | $440.61M(-3.7%) | $139.17M(+31.0%) | $442.07M(+9.6%) |
| Sep 2022 | - | $106.21M(-8.3%) | $403.39M(-3.1%) |
| Jun 2022 | - | $115.77M(+43.1%) | $416.25M(-3.3%) |
| Mar 2022 | - | $80.92M(-19.5%) | $430.44M(-6.0%) |
| Dec 2021 | $457.72M(+16.9%) | $100.49M(-15.6%) | $457.72M(+2.6%) |
| Sep 2021 | - | $119.06M(-8.4%) | $446.03M(+5.0%) |
| Jun 2021 | - | $129.97M(+20.1%) | $424.63M(+14.4%) |
| Mar 2021 | - | $108.20M(+21.9%) | $371.22M(-5.2%) |
| Dec 2020 | $391.70M(+87.6%) | $88.80M(-9.1%) | $391.70M(+9.1%) |
| Sep 2020 | - | $97.67M(+27.6%) | $359.03M(+11.0%) |
| Jun 2020 | - | $76.55M(-40.5%) | $323.36M(+11.3%) |
| Mar 2020 | - | $128.68M(+129.3%) | $290.48M(+39.2%) |
| Dec 2019 | $208.75M(-52.4%) | $56.12M(-9.5%) | $208.75M(-20.9%) |
| Sep 2019 | - | $62.00M(+42.0%) | $263.84M(-20.6%) |
| Jun 2019 | - | $43.67M(-7.0%) | $332.38M(-16.0%) |
| Mar 2019 | - | $46.95M(-57.8%) | $395.82M(-9.8%) |
| Dec 2018 | $438.18M(+50.2%) | $111.22M(-14.8%) | $438.88M(+4.1%) |
| Sep 2018 | - | $130.54M(+21.9%) | $421.46M(+14.2%) |
| Jun 2018 | - | $107.10M(+19.0%) | $369.13M(+14.6%) |
| Mar 2018 | - | $90.02M(-4.0%) | $322.17M(+38.8%) |
| Dec 2017 | $291.65M(+118.5%) | $93.80M(+19.9%) | $232.15M(+42.8%) |
| Sep 2017 | - | $78.21M(+30.0%) | $162.59M(+14.1%) |
| Jun 2017 | - | $60.15M(+148.2%) | $142.45M(+19.5%) |
| Dec 2016 | $133.47M(-14.5%) | - | - |
| Dec 2016 | - | $24.24M(-58.3%) | $119.18M(-18.6%) |
| Sep 2016 | - | $58.06M(+103.5%) | $146.48M(+4.8%) |
| Jun 2016 | - | $28.53M(+241.8%) | $139.78M(-7.5%) |
| Mar 2016 | - | $8.35M(-83.8%) | $151.06M(-3.3%) |
| Dec 2015 | $156.07M(+19.1%) | $51.54M(+0.3%) | $156.27M(+35.1%) |
| Sep 2015 | - | $51.36M(+29.0%) | $115.69M(+16.7%) |
| Jun 2015 | - | $39.82M(+193.8%) | $99.14M(-19.6%) |
| Mar 2015 | - | $13.55M(+23.7%) | $123.32M(-5.9%) |
| Dec 2014 | $131.07M(+117.9%) | $10.96M(-68.5%) | $131.08M(+16.1%) |
| Sep 2014 | - | $34.81M(-45.6%) | $112.88M(+10.8%) |
| Jun 2014 | - | $63.99M(+200.2%) | $101.87M(+70.5%) |
| Mar 2014 | - | $21.32M(+394.3%) | $59.73M(+0.6%) |
| Dec 2013 | $60.16M | -$7.24M(-130.4%) | $59.36M(-54.1%) |
| Sep 2013 | - | $23.81M(+8.9%) | $129.35M(-11.3%) |
| Jun 2013 | - | $21.85M(+4.3%) | $145.77M(-11.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2013 | - | $20.95M(-66.6%) | $165.42M(-0.9%) |
| Dec 2012 | $170.70M(+39.0%) | $62.75M(+56.0%) | $166.98M(+15.2%) |
| Sep 2012 | - | $40.22M(-3.1%) | $144.96M(+6.8%) |
| Jun 2012 | - | $41.51M(+84.4%) | $135.79M(+13.7%) |
| Mar 2012 | - | $22.50M(-44.8%) | $119.38M(-2.8%) |
| Dec 2011 | $122.80M(-70.2%) | $40.74M(+31.2%) | $122.80M(+15.8%) |
| Sep 2011 | - | $31.04M(+23.7%) | $106.00M(-47.6%) |
| Jun 2011 | - | $25.10M(-3.2%) | $202.35M(-12.6%) |
| Mar 2011 | - | $25.93M(+8.3%) | $231.44M(-45.1%) |
| Dec 2010 | $412.36M(+327.9%) | $23.94M(-81.2%) | $421.43M(-9.1%) |
| Sep 2010 | - | $127.39M(+135.1%) | $463.71M(+32.2%) |
| Jun 2010 | - | $54.19M(-74.9%) | $350.75M(+15.2%) |
| Mar 2010 | - | $215.91M(+226.0%) | $304.59M(+216.0%) |
| Dec 2009 | $96.38M(+344.3%) | $66.23M(+359.2%) | $96.38M(+290.4%) |
| Sep 2009 | - | $14.42M(+79.6%) | $24.69M(+788.0%) |
| Jun 2009 | - | $8.03M(+4.3%) | -$3.59M(+69.1%) |
| Mar 2009 | - | $7.70M(+240.9%) | -$11.62M(+39.8%) |
| Dec 2008 | $21.69M(-77.2%) | -$5.46M(+60.6%) | -$19.31M(-39.4%) |
| Sep 2008 | - | -$13.85M(-768.4%) | -$13.85M(-322.8%) |
| Dec 2007 | $95.14M(+1045.1%) | - | - |
| Dec 2006 | $8.31M(+10.4%) | - | - |
| Dec 2005 | $7.53M(+200.7%) | - | - |
| Sep 2004 | - | $2.07M(+24.4%) | $6.21M(+336.8%) |
| Jun 2004 | - | $1.67M(-74.2%) | $1.42M(+198.4%) |
| Mar 2004 | - | $6.45M(+262.4%) | -$1.45M(+85.6%) |
| Dec 2003 | -$7.48M(+58.6%) | -$3.97M(-46.0%) | -$10.03M(+0.5%) |
| Sep 2003 | - | -$2.72M(-126.1%) | -$10.08M(+11.5%) |
| Jun 2003 | - | -$1.20M(+43.8%) | -$11.40M(+26.1%) |
| Mar 2003 | - | -$2.14M(+46.8%) | -$15.41M(+14.6%) |
| Dec 2002 | -$18.05M(+8.2%) | -$4.02M(+0.4%) | -$18.05M(+8.2%) |
| Sep 2002 | - | -$4.04M(+22.7%) | -$19.67M(+5.5%) |
| Jun 2002 | - | -$5.22M(-9.3%) | -$20.82M(-3.3%) |
| Mar 2002 | - | -$4.78M(+15.3%) | -$20.16M(-2.9%) |
| Dec 2001 | -$19.67M(-24.5%) | -$5.64M(-8.9%) | -$19.59M(+4.7%) |
| Sep 2001 | - | -$5.18M(-13.6%) | -$20.56M(-14.9%) |
| Jun 2001 | - | -$4.56M(-8.4%) | -$17.89M(-4.5%) |
| Mar 2001 | - | -$4.21M(+36.4%) | -$17.12M(-8.4%) |
| Dec 2000 | -$15.80M(-122.0%) | -$6.61M(-163.0%) | -$15.80M(-78.3%) |
| Sep 2000 | - | -$2.51M(+33.8%) | -$8.86M(-41.1%) |
| Jun 2000 | - | -$3.80M(-31.9%) | -$6.28M(-107.5%) |
| Mar 2000 | - | -$2.88M(-983.1%) | -$3.03M(-298.8%) |
| Dec 1999 | -$7.12M(-64.0%) | $326.00K(+379.4%) | -$759.00K(+66.5%) |
| Sep 1999 | - | $68.00K(+112.5%) | -$2.26M(+26.8%) |
| Jun 1999 | - | -$542.00K(+11.3%) | -$3.09M(+17.7%) |
| Mar 1999 | - | -$611.00K(+48.1%) | -$3.75M(+13.4%) |
| Dec 1998 | -$4.34M | -$1.18M(-55.0%) | -$4.34M(-37.3%) |
| Sep 1998 | - | -$760.00K(+37.0%) | -$3.16M(-31.7%) |
| Jun 1998 | - | -$1.21M(-1.0%) | -$2.40M(-101.0%) |
| Mar 1998 | - | -$1.19M | -$1.19M |
FAQ
- What is Amneal Pharmaceuticals, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Amneal Pharmaceuticals, Inc.?
- What is Amneal Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is Amneal Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Amneal Pharmaceuticals, Inc.?
- What is Amneal Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is Amneal Pharmaceuticals, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Amneal Pharmaceuticals, Inc.?
- What is Amneal Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is Amneal Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of AMRX is $589.48M
What is the all-time high annual EBITDA for Amneal Pharmaceuticals, Inc.?
Amneal Pharmaceuticals, Inc. all-time high annual EBITDA is $589.48M
What is Amneal Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, AMRX annual EBITDA has changed by +$97.04M (+19.71%)
What is Amneal Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of AMRX is $174.14M
What is the all-time high quarterly EBITDA for Amneal Pharmaceuticals, Inc.?
Amneal Pharmaceuticals, Inc. all-time high quarterly EBITDA is $215.91M
What is Amneal Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, AMRX quarterly EBITDA has changed by +$21.13M (+13.81%)
What is Amneal Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of AMRX is $626.64M
What is the all-time high TTM EBITDA for Amneal Pharmaceuticals, Inc.?
Amneal Pharmaceuticals, Inc. all-time high TTM EBITDA is $626.64M
What is Amneal Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, AMRX TTM EBITDA has changed by +$68.81M (+12.34%)